Proton pump inhibitor therapy and potential long-term harm.
about
The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysisAcid-suppression medications and bacterial gastroenteritis: a population-based cohort study.Potentially inappropriate home medications among older patients with cardiovascular disease admitted to a cardiology service in USA.Proton pump inhibitors: Risks of long-term use.Management of gastrointestinal involvement in scleroderma.Current management of the gastrointestinal complications of systemic sclerosis.Efficacy of DA-9701 (Motilitone) in Functional Dyspepsia Compared to Pantoprazole: A Multicenter, Randomized, Double-blind, Non-inferiority Study.Delirium in the geriatric unit: proton-pump inhibitors and other risk factors.ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.Antioxidant and Anti-Inflammatory Effects of Rhei Rhizoma and Coptidis Rhizoma Mixture on Reflux Esophagitis in RatsHypomagnesemia as a potentially life-threatening adverse effect of omeprazole.A retrospective analysis of the role of proton pump inhibitors in colorectal cancer disease survival.Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease.Proton Pump Inhibitors: The Culprit for Barrett's Esophagus?A medication review and deprescribing method for hospitalised older patients receiving multiple medications.Safety of proton pump inhibitors and risk of gastric cancers: review of literature and pathophysiological mechanisms.Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth.From Harmful Treatment to Secondary Gain: Adverse Event Reporting in Dyspepsia and Gastroparesis.Endoluminal Therapy for Gastroesophageal Reflux Disease: In Between the Pill and the Knife?Use of proton pump inhibitors and mortality after hip fracture in a nationwide study.Adherence with regulatory resolutions on prevention of NSAIDS-related gastrointestinal injury in Italy.Gastroesophageal reflux symptoms not responding to proton pump inhibitor: GERD, NERD, NARD, esophageal hypersensitivity or dyspepsia?Mechanism of bombesin-induced tonic contraction of the porcine lower esophageal sphincter.Adherence to stress-related mucosal damage prophylaxis guideline in patients admitted to the Intensive Care Unit.Impact of Comorbid Irritable Bowel Syndrome on Treatment Outcome in Non-Erosive Reflux Disease on Long-Term Proton Pump Inhibitor in Japan.Diabetes and the Esophagus.A Novel Risk Factor Associated With Colonization by Carbapenemase-Producing Enterobacteriaceae: Use of Proton Pump Inhibitors in Addition to Antimicrobial Treatment.Symptom Management for Patients With Esophageal Cancer After Esophagectomy.Possible Risk Factors for Candida Esophagitis in Immunocompetent Individuals.Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors
P2860
Q21090577-4F37BB89-C2F6-4736-A560-593BF7789C13Q33666086-B5304828-BF2C-40BD-BBF3-712BFE2CA28FQ33912969-41A6F65B-BABA-4B06-878C-1B3F11E3BFD4Q34549406-010519D3-C58D-4D7A-A3CD-BC7001E91B51Q35624333-D1BB2244-32BA-4BEF-BCE5-7B97CA3D8DDDQ36068493-BC9156C5-8765-4EA6-A0EF-ECE55A05FED4Q36762648-FEA7D931-943A-499B-9120-8F7D680681F1Q36786953-582D6454-20EB-411E-9E12-C618AFF35A00Q36849357-DF73FAC8-3D76-4120-A360-B5960D20BE4CQ36889807-B534BEC5-05BB-4207-BEC6-FB6C7C1E17B0Q37130559-3C6D00B5-9C0C-486E-9B05-FA6AAC310D72Q37524960-636D82A5-E171-4BBC-9AD6-2D3F51ADF5BCQ38229080-943979AA-2597-421B-A55F-381A7B075503Q38332589-3FEA2B23-4103-4781-A94F-DC269050ACA5Q38589894-51C0647B-04F6-43FF-9921-55C6B8D62FACQ38631128-BA8F4943-3DAF-4FAD-8195-38C05AF9BBD9Q38645247-B30433B3-283C-4A0A-AE8B-1FE695FB45EBQ38747262-2A1FEBC0-DC43-4332-A073-4E6005F1B5BCQ38994721-7394D2CE-E808-435F-A4F5-A2B475F70E8AQ39023035-259130A9-BB59-4DD4-BDA8-51D55F3C6EDDQ39898020-25A4CDCD-CBB9-4219-9CED-FF0D4BCAFC2AQ41267128-014F309A-A81B-42B8-BD18-F958E74FD4CDQ41830409-1618113B-8F51-4957-8ECA-AA8089E4D1C4Q42394355-A65DC3E0-B04D-4D22-8D43-F7C62692F28FQ47847807-D451EECD-9B6C-410E-BB95-E939D5CC9EEFQ50075786-0C9DC6DE-2398-4526-9F5F-01B78DF794F5Q53770049-B82BB42D-05C6-44E3-8445-F5036F2F5F0EQ55285408-243EDEEB-DA9E-4684-A67E-78D2DE97AE66Q55362825-2C88B689-83A3-4A23-A17B-05D0D97EA491Q57271829-19131362-A198-4C04-A9DB-DB6EA501A438
P2860
Proton pump inhibitor therapy and potential long-term harm.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Proton pump inhibitor therapy and potential long-term harm.
@ast
Proton pump inhibitor therapy and potential long-term harm.
@en
Proton pump inhibitor therapy and potential long-term harm.
@nl
type
label
Proton pump inhibitor therapy and potential long-term harm.
@ast
Proton pump inhibitor therapy and potential long-term harm.
@en
Proton pump inhibitor therapy and potential long-term harm.
@nl
prefLabel
Proton pump inhibitor therapy and potential long-term harm.
@ast
Proton pump inhibitor therapy and potential long-term harm.
@en
Proton pump inhibitor therapy and potential long-term harm.
@nl
P2093
P1476
Proton pump inhibitor therapy and potential long-term harm
@en
P2093
Emilio Di Giulio
Stefano Festa
Vito Domenico Corleto
P356
10.1097/MED.0000000000000031
P577
2014-02-01T00:00:00Z